Get the Stockscreener App
27.54
3.33%
-0.95
After Hours:
27.60
0.06
+0.22%
Moderna Inc stock is traded at $27.54, with a volume of 8.34M.
It is down -3.33% in the last 24 hours and up +9.55% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$28.49
Open:
$28.49
24h Volume:
8.34M
Relative Volume:
0.83
Market Cap:
$10.72B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.1546
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+8.72%
1M Performance:
+9.55%
6M Performance:
+9.68%
1Y Performance:
-54.25%
1-Day Range:
$27.48
$28.67
1-Week Range:
$24.56
$28.99
52-Week Range:
$23.15
$60.65
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.54 | 11.08B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.90 | 103.40B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.48 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
787.94 | 48.96B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
344.53 | 37.77B | 4.56B | -176.77M | 225.30M | -1.7177 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna (MRNA) COVID-19 Booster Recommendations Updated by CDC - GuruFocus
CDC adopts individual-based decision-making for COVID-19 shots (MRNA:NASDAQ) - Seeking Alpha
Moderna - WCIV
Will Moderna Inc. see short term momentum2025 Year in Review & Fast Moving Stock Trade Plans - newser.com
Key metrics from Moderna Inc.’s quarterly data2025 EndofYear Setup & Step-by-Step Swing Trade Plans - newser.com
Day 5 of Gains Streak for Moderna Stock with 16% Return (vs. -31% YTD) [10/3/2025] - Trefis
Moderna Inc. (MRNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - Greenville Online
Moderna Says GSK ‘Abusing’ Patents to Siphon Covid Shot Profits - Bloomberg Law News
How to interpret RSI for Moderna Inc. stockMarket Risk Analysis & Smart Allocation Stock Reports - newser.com
Moderna (MRNA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
The CDC still hasn't issued COVID vaccine guidelines, leaving access in limbo - NPR
What to know about this fall’s COVID-19 vaccine - The Globe and Mail
November 14th Options Now Available For Moderna (MRNA) - Nasdaq
6 Healthcare Stocks Positioned to Soar After Trump-Pfizer Deal - Investing.com
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency? - The Globe and Mail
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
Union Bancaire Privee UBP SA Sells 15,518 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Sold by Public Employees Retirement System of Ohio - MarketBeat
Brookline Reaffirms Price Target for Moderna (MRNA) After Strong mRNA-1283 Vaccine Results - Yahoo
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK - Detroit Free Press
Moderna Stock Is Rallying Wednesday: What's Driving The Action? - Benzinga
Moderna (NASDAQ:MRNA) Shares Up 5.9%Here's Why - MarketBeat
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Moderna (MRNA) Continues Upward Trend in Early Trading - GuruFocus
What high frequency data says about Moderna Inc.2025 Investor Takeaways & Low Volatility Stock Recommendations - newser.com
mRNA Vaccine and Therapeutics Market to Hit USD 127.8 Billion by 2034, Growing at 10.7% CAGR - openPR.com
Applying chart zones and confluence areas to Moderna Inc.Market Activity Summary & Low Risk High Win Rate Stock Picks - newser.com
Tools to assess Moderna Inc.’s risk profileGDP Growth & Pattern Based Trade Signal System - newser.com
Automated trading signals detected on Moderna Inc.IPO Watch & Weekly Watchlist for Hot Stocks - newser.com
mRNA Market Forecasted to Reach USD 128.6 Billion by 2034, Key Players: Moderna & Pfizer/BioNTech - openPR.com
2 Beaten-Down Stocks to Buy and Hold for a Decade - Yahoo Finance
Chart based exit strategy for Moderna Inc.2025 Market WrapUp & Daily Price Action Insights - newser.com
Moderna, Inc. (MRNA) Stock Analysis: Navigating the 80.69% Potential Upside Amidst Challenges - DirectorsTalk Interviews
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 - The Daily Jeffersonian
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 - The Daily Jeffersonian
Moderna, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Moderna Announces Data to be Presented at ESMO Congress 2025 - The Daily Jeffersonian
Is Moderna Inc. stock cheap compared to fundamentals2025 Historical Comparison & Consistent Growth Stock Picks - newser.com
Moderna to Present at Upcoming Conferences in June 2025 - Norwich Bulletin
Bank Pictet & Cie Europe AG Grows Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna (MRNA) Dips More Than Broader Market: What You Should Know - sharewise.com
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.36%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):